Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of QP-6211 injection for postoperative analgesia after hemorrhoidectomy
CTR20251672Phase 3Completed
- Sponsor
- ClearPoint Biotech
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QP-6211 in postoperative pain (3 arms), sponsored by ClearPoint Biotech. Primary endpoint: Area under the curve (AUC) of planned time-point pain intensity scores from postoperative period to 72 hours after dosing. Started May 2025; status: completed.
02
Drugs
QP-6211
03
Conditions
postoperative pain
Beyond the preview
Go deeper on CTR20251672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251672.